Key Takeaways
- Domestic formulations lead, crossing INR 400 crore: Organic growth in the mid-teens outpaced a flat IPM, making J.B. the fastest-growing top-25 company. Prescriptions surged 57% YoY to 4.09 crore.
- CMO business hits a record INR 100 crore quarter: Cough-and-cold demand that began in Q4 FY22 continued, and a robust order book supports a front-loaded H1. The segment is expected to reach 13–14% of full-year revenue.
- Margins compressed by inflation and investment: Gross margin fell to ~63% as input costs and Azmarda-related air-freighting bit, while employee costs rose 19% on increments and acquisition integration. EBITDA margin is guided to a volatile 24–26% band for FY23.
- Azmarda is a bet on a post-LOE future: The brand is in investment mode with a INR 7–8 crore monthly run rate and negative EBITDA. Management is racing to build a diagnosed patient base before patent expiry in December 2022, after which it expects significant margin relief.
- What to watch next quarter: Whether the CMO order book converts at the high end of the plus/minus 10% range, the trajectory of gross margin recovery as commodity tailwinds meet fuel headwinds, and any early signs of the Sanzyme life-cycle management launches gaining traction.
Domestic Formulations: The Growth Engine
- Prescription velocity: The 57% YoY jump to 4.09 crore prescriptions was driven by enhanced field-force productivity and a focus on chronic therapies. Management aspires to reach 6 crore prescriptions over time by deepening engagement with existing doctors rather than expanding coverage.
- Big brands gaining share: Metrogyl, Cilacar-T, and Nicardia each improved their rankings within the IPM Top 300. Cilacar grew 14–16%, while Rantac and Metrogyl managed low double-digit growth on a very high base.
- Specialist focus: The agenda is to extract more prescriptions per doctor from cardiologists, nephrologists, paediatricians, chest physicians, and diabetologists. The field force of 2,500 will not be expanded in the short-to-mid term.
- Ranking milestone: J.B. Pharma now stands at number 15 in the IPM as per IQVIA, reflecting sustained share gains.
Chopra: "So we are looking organization from a theme of invest to grow, that is what is the intention."
CMO Business: Record Scale and Front-Loaded Demand
- Record quarter: The CMO segment surpassed INR 100 crore in revenue for the first time, up from ~INR 83 crore in Q4 FY22. End-customer demand for the cough-and-cold portfolio, which surged in mid-Q4 last year, continued through Q1.
- Order book visibility: A robust order book exists for at least the next 3–4 months, with management expecting demand within a plus/minus 10% band. The business is structurally front-loaded, with H1 typically stronger than H2 due to stocking patterns for calendar Q2 and Western holiday schedules.
- Q2 trajectory: Revenue is expected to land between the Q4 (~INR 83 crore) and Q1 (INR 100 crore) figures. Full-year growth is pegged at mid-teens, with the segment contributing 13–14% of overall revenue versus 10% last year.
- Capacity and new partners: Existing lozenge capacity of 200 crore units comfortably exceeds the current 100 crore-plus output, so no major capex is needed. The partnership with Reckitt has expanded from Australia into discussions for Russia and Southeast Asia, and proof-of-concept work is underway in new categories like sleep disorders and sexual wellness.
Chopra: "Probably the stocking part happens for us, calendar quarter is quarter 2. That is how things happen. And if the end customer demand continues to be there, then it should surprise all of us."
Azmarda: The Pre-LOE Investment Bet
- Investment-mode brand: Azmarda (sacubitril/valsartan) is running at a INR 7–8 crore monthly run rate with dedicated teams promoting to cardiologists and physicians. The strategy centers on building a critical mass of diagnosed heart failure patients via 2D/3D echo before the molecule’s patent expires in December 2022.
- Negative profitability today: The brand is currently at negative EBITDA, and its drag on gross margin is significantly higher than the 90 bps an analyst estimated, because the transition period required extra costs like air freighting and sourcing to ensure supply continuity.
- Post-LOE margin aspiration: Management expects more than 50 players to enter after LOE, triggering price erosion, but believes the brand will retain value. The minimum margin aspiration post-LOE is slightly better than the company average EBITDA, with significant gross margin relief expected in Q4.
- Therapy conviction: Management views sacubitril/valsartan as the primary therapy in heart failure, expecting that once LOE expires and price points converge with dapagliflozin, uptake will accelerate.
Chopra: "We are keeping fingers crossed in terms of the overall strategy that we will put in place when the LOE sets in. And right now, what is stopped on the agenda is to how to at least have critical mass of patients who are getting diagnosed..."
Sanzyme Acquisition: Integration and Life-Cycle Management
- Sporlac momentum: The flagship probiotic brand grew 26% versus competitor growth of 18–20%, gaining market share. The monthly run rate is INR 12–13 crore with mid-to-high teens growth, and benefits from J.B.’s prescriber base and geographical footprint are starting to materialize.
- Full-year target: Revenue traction is expected between INR 140 crore and INR 150 crore for the year. The business is seasonally stronger in H1, with probiotic demand tapering from Q3 onward.
- Life-cycle management pipeline: New premium-priced Sporlac variants are expected in the next couple of months. The company is also on the verge of addressing portfolio gaps in the infertility segment and has seen a June uptick in high-priced probiotics like Oxalo/Lobun for chronic kidney disease, where J.B. covers all 2,000 nephrologists.
- Payback ambition: While the standard acquisition payback period is 6 years, management is aiming for a sub-6-year payback on both Sanzyme and Azmarda, with expiration returns expected to be much higher than committed to the Board.
Kataria: "We've invested it in a business called Sanzyme, which we brought EBITDA of about INR 50 crore a year. We feel that this INR 50 crore in the next 4 to 5 years can become INR 100 crore, right? That's our hypothesis and that was the whole logic of buying this business."
International Markets: Steady with Pockets of Traction
- South Africa: Both public and private generics business continued to perform well, driving over 25% growth. New product launches are on the path, though management declined to share specifics on the call.
- Russia and CIS: Demand held steady year-on-year despite a challenging environment, with Q1 not the strongest quarter due to portfolio seasonality. Receivables traction has been decent, and traction is expected to improve sequentially from July/August. No change to strategy.
- RoW launches: New product launches are planned in cardiology and diabetology for next year, with a more progressive approach in these therapy areas.
Margins and Profitability: A Volatile Bridge
- Gross margin compression: Gross margin declined to ~63% from 64–65% YoY, hit by inflationary pressure in input and packing material costs. Excluding the Azmarda drag, gross margins were relatively flat. Management hopes to sustain closer to 64% for the full fiscal, with improvement coming through as Azmarda margins recover post-LOE.
- Operating cost stack: Employee expenses rose 19% YoY (excluding ESOP) on annual increments and integration of acquired workforces. Other operating expenses normalized post-COVID and absorbed freight, power, and fuel inflation, plus the opex of acquired businesses. Depreciation was elevated due to amortization of acquired brands.
- PAT decline explained: The 12% YoY PAT decline reflects higher treasury income in the base quarter, non-cash ESOP costs not present a year ago, depreciation on acquired brands, and finance costs. Management expects PAT to enter an upward trajectory in 1–2 quarters as ESOP costs stabilize and treasury income normalizes.
- ROCE path: Management believes it can return to 30–35% ROCE over the next 3–4 years with the current portfolio, contingent on further M&A strategy and investments.
Chopra: "So that is our guidance that we are putting across because you are living in a very volatile world. Please understand the overall geopolitical issues, the currencies, the receivables, all those things have to put in place."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CMO full-year revenue share | Close to 13–14% of overall business (vs 10% last year) | FY23 |
| CMO Q2 revenue | Between Q4 (~INR 83 crore) and Q1 (INR 100 crore) figures | Q2 FY23 |
| CMO full-year growth | Mid-teens growth, front-loaded in H1 | FY23 |
| Sanzyme full-year revenue | INR 140 crore to INR 150 crore | FY23 |
| Sanzyme new product launches | 1–2 life-cycle management products to offset H2 seasonality; new Sporlac variants | Next 2–3 months |
| Azmarda gross margin relief | Some relief in Q3; significant improvement when LOE expires | Q3/Q4 FY23 |
| Azmarda post-LOE margin | Minimum aspiration: slightly better than company average EBITDA | Post-December 2022 |
| Gross margin | Hope to sustain closer to 64% for the fiscal | FY23 |
| EBITDA margin | 24% to 26% band, with quarterly volatility | FY23 |
| PAT trajectory | Upward trajectory as ESOP and treasury income normalize | 1–2 quarters |
| ROCE | Return to 30–35% | Next 3–4 years |
| Prescription aspiration | Grow from 4 crore to 6 crore | "In coming time" |
| Paediatric brands performance update | More information on tax rate and acquisition performance | Q3 FY23 onwards |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹785 cr, +30% YoY (20% organic, rest from acquisitions) |
| Domestic formulations revenue | ₹418 cr, all-time high; organic growth in mid-teens as compared to flat growth as reported in IPM |
| International business revenue | ₹366 cr, growth both YoY and QoQ |
| Gross margin | Close to 63%, vs 64% in Q1 FY22; excluding Azmarda, gross margins were relatively flat |
| Operating EBITDA | ₹190 cr, +16% YoY; includes non-cash ESOP charge of ₹17 cr |
| Operating EBITDA margin | 24% plus, in line with 24%–26% guidance for FY23 |
| PAT | ₹105 cr, -12% YoY, due to higher treasury income in base quarter, non-cash ESOP cost, depreciation of acquired brands, and finance costs |
| Employee expenses growth (ex-ESOP) | +19% YoY, on account of annual increments and integration of acquired workforce |
| Net debt | ₹325 cr, largely to fund Azmarda acquisition; cash and investments over ₹180 cr |
| Domestic prescription base | 4.09 cr, +57% YoY (like-for-like per IQVIA) |
| IPM prescription ranking | Number 15, as per IQVIA |
| CMO segment revenue | ₹100 cr, ever highest; Q4 FY22 was ~₹83 cr |
| Sanzyme portfolio monthly run rate | ₹12–13 cr, growing mid to high teens; full-year revenue traction expected ₹140–150 cr |
| Azmarda monthly run rate | ₹7–8 cr, currently negative at EBITDA level |
| South Africa growth | Upwards of 25% YoY, with public-private mix roughly 50-50 |
| Field force size | 2,500 people, up from 2,000 organically, with 300 from Sanzyme and 200 from Azmarda |